Home › Funds › DekaBank Deutsche Girozentrale › ABT

DekaBank Deutsche Girozentrale position in ABT

ABBOTT LABORATORIES · Health Care

DekaBank Deutsche Girozentrale reported holding 4,036,124 shares of ABT (ABBOTT LABORATORIES) in its Q3 2026 13F filing — a position valued at US$407.3M, representing 0.46% of its reported portfolio and ranking #35 among its reported holdings. DekaBank Deutsche Girozentrale has disclosed ABT holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)4.04M sh
Reported value held$407.32M
Portfolio Weight0.46%
First reportedQ3 2023
Last changeAdd
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How DekaBank Deutsche Girozentrale's ABT position evolved

DekaBank Deutsche Girozentrale first disclosed a stake in ABT in Q3 2023 at 2,730,190 shares (US$267.5M). The position peaked in Q3 2026 at 4,036,124 shares, worth US$407.3M. Across 13 filings, DekaBank Deutsche Girozentrale increased the stake 2 time(s), trimmed it 4 time(s) and left it unchanged 6 time(s). The most recent filing (Q3 2026) shows 4,036,124 shares valued at US$407.3M — an increase of 1,492,845 shares quarter over quarter.. Notable position changes include a 59% increase in Q3 2026 (shares rose 10% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 2.73M $267.51M New
Q4 2023 2.72M $299.86M Hold
Q1 2024 2.66M $302.99M Reduce
Q2 2024 2.62M $276.43M Reduce
Q3 2024 2.54M $285.32M Reduce
Q4 2024 2.54M $290.30M Hold
Q1 2025 2.66M $348.75M Add
Q2 2025 2.54M $344.23M Reduce
Q3 2025 2.54M $337.85M Hold
Q4 2025 2.54M $298.89M Hold
Q1 2026 2.54M $262.95M Hold
Q2 2026 2.54M $257.63M Hold
Q3 2026 4.04M $407.32M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About ABT and 13F data

ABT (ABBOTT LABORATORIES) is a Health Care company. 21 other funds we track also report a position in ABT — the largest reported positions include Vanguard Group (US$22.00B), Charles Schwab Investment Management (US$5.41B), CHARLES SCHWAB INVESTMENT MANAGEMENT INC (US$5.41B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding ABT

All ABT fund holders →

FAQ

How long has DekaBank Deutsche Girozentrale held ABT?

DekaBank Deutsche Girozentrale has disclosed ABT holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is DekaBank Deutsche Girozentrale's current position in ABT?

As of Q3 2026, DekaBank Deutsche Girozentrale holds 4.04M shares of ABT (ABBOTT LABORATORIES), valued at $407.32M, representing 0.46% of its reported portfolio and ranking #35.

Has DekaBank Deutsche Girozentrale been buying or selling ABT?

In the latest 13F filing (Q3 2026), DekaBank Deutsche Girozentrale increased its position in ABT. The position peaked in Q3 2026 at 4.04M shares.

Which other funds hold ABT?

Other major institutional holders of ABT include Vanguard Group, Charles Schwab Investment Management, CHARLES SCHWAB INVESTMENT MANAGEMENT INC, among 21 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.